Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Shingrix late second dose; This non-serious case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in September 2019). In JUL-2025, the patient received the 2nd dose of Shingrix. In JUL-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 15-OCT-2025 A medical inquiry was received regarding a patient who had taken Shingrix in September 2019 and then received a second dose in July 2025. The visitor asked if a third dose was needed. They mentioned that the CDC appeared to indicate no, but some colleagues believed a third dose was necessary for their patients. The agent asked if those colleagues might have administered third doses due to delayed schedules. The visitor responded that it was possible, as the second dose had been given after the patient missed the recommended 3 to 6-month interval. No follow-up was granted. The batch number was not provided upon follow up with the reporter.